Phase Ib/II Trial of Olaparib with AZD2014 or AZD5363 in Recurrent Endometrial and Ovarian Cancer
This trial evaluates the safety and optimal dosing of olaparib in combination with either vistusertib or capivasertib for recurrent cancers.
Phase III
recurrent endometrial cancer
Status
Active
Sponsor
AstraZeneca
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Why it matters
The ongoing trial of olaparib in combination with mTORC1/2 and AKT inhibitors is significant as it may redefine treatment protocols for recurrent endometrial and ovarian cancers. AstraZeneca's positioning in the oncology market could be strengthened depending on the trial outcomes, particularly against competing PARP inhibitors.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor trial results for efficacy and safety data, as well as any potential regulatory filings based on outcomes.
Related companies & assets
Companies
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.